Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: BLCO )

17.05 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 17.05
Bid (Size) 16.50 (1)
Ask (Size) 18.75 (2)
Prev. Close 17.05
Today's Range 17.05 - 17.05
52wk Range 12.79 - 21.95
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners
From Bausch + Lomb Corporation
Via Business Wire

Performance

YTD
+8.46%
+8.46%
1 Month
-6.47%
-6.47%
3 Month
-13.76%
-13.76%
6 Month
+1.55%
+1.55%
1 Year
+9.09%
+9.09%

More News

Read More
Bausch + Lomb Announces Pricing of Senior Secured Notes Offering
From Bausch + Lomb Corporation
Via Business Wire
Earnings Preview: Bausch & Lomb
Via Benzinga
Analyst Ratings for Bausch & Lomb
Via Benzinga
Analyst Ratings for Bausch & Lomb
Via Benzinga
Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
Via FinancialNewsMedia
Exposures COVID-19
Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Solidifies Leadership Team
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink
Via Benzinga
Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops
From Bausch + Lomb Corporation
Via Business Wire
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
Via Benzinga
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
Via Benzinga
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Via Benzinga
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Will Acquire XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10 in the United States
From Bausch + Lomb Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.